Show simple item record

dc.contributor.authorCatala-Lopez, Ferran 
dc.contributor.authorHutton, Brian
dc.contributor.authorDriver, Jane A
dc.contributor.authorPage, Matthew J
dc.contributor.authorRidao, Manuel
dc.contributor.authorValderas, José M
dc.contributor.authorAlonso-Arroyo, Adolfo
dc.contributor.authorForés-Martos, Jaume
dc.contributor.authorMartínez, Salvador
dc.contributor.authorGènova-Maleras, Ricard
dc.contributor.authorMacías-Saint-Gerons, Diego
dc.contributor.authorCrespo-Facorro, Benedicto
dc.contributor.authorVieta, Eduard
dc.contributor.authorValencia, Alfonso 
dc.contributor.authorTabarés-Seisdedos, Rafael
dc.identifier.citationSyst Rev. 2017 ;6(1):69.es_ES
dc.description.abstractBACKGROUND: The objective of this study will be to synthesize the epidemiological evidence and evaluate the validity of the associations between central nervous system disorders and the risk of developing or dying from cancer. METHODS/DESIGN: We will perform an umbrella review of systematic reviews and conduct updated meta-analyses of observational studies (cohort and case-control) investigating the association between central nervous system disorders and the risk of developing or dying from any cancer or specific types of cancer. Searches involving PubMed/MEDLINE, EMBASE, SCOPUS and Web of Science will be used to identify systematic reviews and meta-analyses of observational studies. In addition, online databases will be checked for observational studies published outside the time frames of previous reviews. Eligible central nervous system disorders will be Alzheimer's disease, anorexia nervosa, amyotrophic lateral sclerosis, autism spectrum disorders, bipolar disorder, depression, Down's syndrome, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease and schizophrenia. The primary outcomes will be cancer incidence and cancer mortality in association with a central nervous system disorder. Secondary outcome measures will be site-specific cancer incidence and mortality, respectively. Two reviewers will independently screen references identified by the literature search, as well as potentially relevant full-text articles. Data will be abstracted, and study quality/risk of bias will be appraised by two reviewers independently. Conflicts at all levels of screening and abstraction will be resolved through discussion. Random-effects meta-analyses of primary observational studies will be conducted where appropriate. Parameters for exploring statistical heterogeneity are pre-specified. The World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) criteria and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used for determining the quality of evidence for cancer outcomes. DISCUSSION: Our study will establish the extent of the epidemiological evidence underlying the associations between central nervous system disorders and cancer and will provide a rigorous and updated synthesis of a range of important site-specific cancer outcomes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42016052762.es_ES
dc.description.sponsorshipSpecific funding from the Generalitat Valenciana (PROMETEOII/2015/021) and CIBERSAM/Institute of Health Carlos III was received for this work. The funders were not involved in the design of the protocol or decision to submit the protocol for publication nor will they be involved in any aspect of the conduct of the review. BH is supported by a New Investigator Award from the Canadian Institutes of Health Research and the Drug Safety and Effectiveness Network. MJP is supported by an Australian National Health and Medical Research Council Early Career Fellowship (1088535). MR is partially funded by the Spanish Health Services Research on Chronic Patients Network (REDISSEC)/Institute of Health Carlos III. The views expressed in this article are the views of the authors and may not be understood or quoted as being made on behalf of, or reflecting the position of, the funder(s) or any institution.CIBERSAM/Institute of Health Carlos III.es_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectAlzheimer’s diseasees_ES
dc.subjectAmyotrophic lateral sclerosises_ES
dc.subjectAnorexia nervosaes_ES
dc.subjectAutism spectrum disorderses_ES
dc.subjectBipolar disorderes_ES
dc.subjectCentral nervous system disorderes_ES
dc.subjectDown’s syndromees_ES
dc.subjectHuntington’s diseasees_ES
dc.subjectMultiple sclerosises_ES
dc.subjectParkinson’s diseasees_ES
dc.subjectSystematic reviewes_ES
dc.subject.meshCentral Nervous System Diseases es_ES
dc.subject.meshHumans es_ES
dc.subject.meshIncidence es_ES
dc.subject.meshMeta-Analysis as Topic es_ES
dc.subject.meshNeoplasms es_ES
dc.subject.meshObservational Studies as Topic es_ES
dc.subject.meshResearch Design es_ES
dc.subject.meshSystematic Reviews as Topic es_ES
dc.subject.meshReview Literature as Topic es_ES
dc.titleCancer and central nervous system disorders: protocol for an umbrella review of systematic reviews and updated meta-analyses of observational studieses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.contributor.funderGeneralitat Valencianaes_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIII (España)es_ES
dc.contributor.funderCanadian Institutes of Health Research (CIHR)es_ES
dc.contributor.funderDrug Safety and Effectiveness Networkes_ES
dc.contributor.funderNational Health and Medical Research Council of Australiaes_ES
dc.contributor.funderSpanish Health Services Research on Chronic Patients Network (REDISSEC)/es_ES
dc.identifier.journalSystematic reviewses_ES
dc.repisalud.orgCNIOCNIO::Grupos de investigación::Antiguos CNIOes_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional